Rating rater improvement: a method for estimating increased effect size and reduction of clinical trial costs - PubMed (original) (raw)

Rating rater improvement: a method for estimating increased effect size and reduction of clinical trial costs

Kenneth O Cogger. J Clin Psychopharmacol. 2007 Aug.

No abstract available

PubMed Disclaimer

Similar articles

• A comparative meta-analysis of Clinical Global Impressions change in antidepressant trials.
  Spielmans GI, McFall JP. Spielmans GI, et al. J Nerv Ment Dis. 2006 Nov;194(11):845-52. doi: 10.1097/01.nmd.0000244554.91259.27. J Nerv Ment Dis. 2006. PMID: 17102709
• From trial and error to trial simulation. Part 1: the importance of model-based drug development for antidepressant drugs.
  Santen G, van Zwet E, Danhof M, Della Pasqua O. Santen G, et al. Clin Pharmacol Ther. 2009 Sep;86(3):248-54. doi: 10.1038/clpt.2009.105. Epub 2009 Aug 5. Clin Pharmacol Ther. 2009. PMID: 19657333 Review.
• Comments on "Clinical trials of antidepressants: time to shift to a new model" by Dr Katz.
  Rickels K, Robinson DS. Rickels K, et al. J Clin Psychopharmacol. 2009 Apr;29(2):197-8; author reply 198-9. doi: 10.1097/JCP.0b013e318199f275. J Clin Psychopharmacol. 2009. PMID: 19512995 No abstract available.
• The mousetrap: managing the placebo effect in antidepressant trials.
  Lakoff A. Lakoff A. Mol Interv. 2002 Apr;2(2):72-6. doi: 10.1124/mi.2.2.72. Mol Interv. 2002. PMID: 14993352 Review. No abstract available.
• Generalizability of antidepressant efficacy trials.
  Zimmerman M, Posternak MA, Chelminski I. Zimmerman M, et al. Essent Psychopharmacol. 2004;6(1):45-58. Essent Psychopharmacol. 2004. PMID: 15612653 Review. No abstract available.

Cited by

• Alzheimer's disease drug development: old problems require new priorities.
  Becker RE, Greig NH. Becker RE, et al. CNS Neurol Disord Drug Targets. 2008 Dec;7(6):499-511. doi: 10.2174/187152708787122950. CNS Neurol Disord Drug Targets. 2008. PMID: 19128207 Free PMC article. Review.
• Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?
  Becker RE, Greig NH, Giacobini E. Becker RE, et al. J Alzheimers Dis. 2008 Oct;15(2):303-25. doi: 10.3233/jad-2008-15213. J Alzheimers Dis. 2008. PMID: 18953116 Free PMC article. Review.
• Why so few drugs for Alzheimer's disease? Are methods failing drugs?
  Becker RE, Greig NH. Becker RE, et al. Curr Alzheimer Res. 2010 Nov;7(7):642-51. doi: 10.2174/156720510793499075. Curr Alzheimer Res. 2010. PMID: 20704560 Free PMC article. Review.
• Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?
  Becker RE, Greig NH. Becker RE, et al. J Clin Psychopharmacol. 2009 Feb;29(1):56-64. doi: 10.1097/JCP.0b013e318192e2fa. J Clin Psychopharmacol. 2009. PMID: 19142109 Free PMC article.
• Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?
  Becker RE, Greig NH. Becker RE, et al. Alzheimers Dement. 2013 Jan;9(1):50-7. doi: 10.1016/j.jalz.2012.01.007. Epub 2012 Mar 30. Alzheimers Dement. 2013. PMID: 22465172 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wolters Kluwer

• Medical

  • MedlinePlus Health Information